Search
SOLACI Congress
HomeTCT 2017HEART DISEASE

HEART DISEASE

View Category
Chronic Ischemic cardiopathy

TCT 2017 | FAME 2 at 3 Years: Better Results with Angioplasty and at a Cost Similar to Medical Treatment

Courtesy of SBHCI. Angioplasty in patients with chronic stable angina and functionally significant lesions improves clinical outcomes and...
solaci -
Learn More
Chronic Ischemic cardiopathy

TCT 2017 | ORBITA: The Placebo Effect of Angioplasty

Courtesy of the SBHCI. Chronic stable angina and severe coronary lesion patients who undergo angioplasty in a single...
solaci -
Learn More
Antiplatelet

TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients

 Courtesy of the SBHCI. This study sought to assess the safety and efficacy of an everolimus-eluting stent with...
solaci -
Learn More
Acute coronary syndromes

TCT 2017 | REDUCE: 3 vs 12 Months of Dual Antiplatelet Therapy with the New Combo DES

Courtesy of SBHCI. This new device has, on one hand, an abluminal sirolimus coating, and on the other...
solaci -
Learn More
Coronary disease

ABSORB III: after 3 Years, the Bioresorbable Scaffold is Still a Disappointment

Courtesy of the SBHCI. The 3-year outcomes of the ABSORB III trial, which randomized 2008 patients 2:1 to...
solaci -
Learn More
Coronary disease

Absorb IV: Bioresorbable Scaffolds with an Optimized Implantation Technique

 Courtesy of the SBHCI. The Absorb IV trial randomized 2604 patients in a 1:1 ratio to receive an Absorb everolimus-eluting...
solaci -
Learn More
Coronary disease

ABSORB II: No Benefits from Scaffolds After Complete Bioresorption

 Courtesy of the SBHCI. The ABSORB II study sought to assess the mechanical properties of everolimus-eluting bioresorbable scaffolds, such...
solaci -
Learn More
Bifurcations

DKCRUSH-V: What Is Simple Is Not Always Best for the Left Main Coronary Artery

Courtesy of the SBHCI. Angioplasty of true distal left main bifurcation lesions with a double-kissing (DK) crush two-stent...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Institutional News

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy